Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2023-07-31 Director's Dealing
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Final Director's Interest Notice 2 pages 237.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including the number and class of shares held, and the date the director ceased to be a director. This is a report of personal share transactions or holdings by a company director. The document length is short (2314 characters) and contains specific information about director share interests, which matches the definition of Director's Dealing filings. There is no indication that this is an announcement of a report or a certification, so it is not Regulatory Filings or Report Publication Announcement. Therefore, the correct classification is Director's Dealing (DIRS).
2023-07-31 English
Notification of cessation of securities - MYX 4 pages 23.9KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation (lapse) of certain securities (performance rights) by Mayne Pharma Group Limited. It details the number of securities that have ceased, the reason for cessation, and the updated issued capital following these changes. There is no financial data, no report attached or referenced, and no mention of a meeting or voting results. This type of announcement fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about changes in issued capital securities but does not qualify as a full financial report or capital change announcement (which would involve new issues or capital increases). The document length is short and focused on a specific regulatory disclosure.
2023-07-30 English
Non-Executive Director retirement 1 page 112.7KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement about the retirement of a non-executive director from the company's board. It contains no financial data, no report or presentation, and no mention of voting results or other regulatory filings. The content is specifically about a change in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming the classification.
2023-07-26 English
Change in substantial holding 3 pages 313.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under Corporations Law Section 671B. It details changes in voting power and relevant interests of a substantial shareholder (Viburnum Funds Pty Ltd) in Mayne Pharma Group Limited. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure of shareholding changes.
2023-07-25 English
Update - Notification of buy-back - MYX 6 pages 27.7KB
Transaction in Own Shares Classification · 100% confidence The document is a detailed notification of a daily buy-back of shares by Mayne Pharma Group Limited. It includes specifics such as the number of securities bought back, prices paid, dates, broker information, and regulatory compliance details related to the buy-back. This matches the description of a Transaction in Own Shares (POS) filing, which reports the company's share repurchase activities. The document is not an announcement of a report, nor is it a financial report or certification. Therefore, the correct classification is POS with high confidence.
2023-07-02 English
Update - Notification of buy-back - MYX 6 pages 27.7KB
Transaction in Own Shares Classification · 100% confidence The document is a detailed notification of a buy-back by Mayne Pharma Group Limited. It includes specifics such as the type of buy-back (on-market), dates, number of securities bought back, prices paid, broker information, and regulatory compliance details. The content is focused on the company's repurchase of its own shares and daily updates related to this activity. There is no indication of financial statements, earnings data, management discussion, or other report types. The document matches the description of a Transaction in Own Shares (POS) filing, which reports on share repurchase activities.
2023-06-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.